From patients to discoveriesCRYOSTEM, a national cohort dedicated to the complications of Hematopoietic Stem Cell Transplantation (HSCT)
Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation.
Today, CRYOSTEM brings together 33 of the 36 regional transplant units, 23 Biological Resource Centers, over 400 French research and healthcare players in the field of blood-related diseases and already over 4,500 patients.
This national collective gave rise to the CRYOSTEM Cohort, a collection, unique in Europe, of over 148,000 biological samples, before and after transplant, of 4,500 patients and 1,700 matched sibling donors (data December 2016). From this resource with very high biological and clinical value added, scientists around the world attempt to extract new knowledge allowing them to better prevent, diagnose and treat the complications of HSCT.
All the research projects supported by CRYOSTEM meet rigorous selection criteria, defined by a scientific committee that brings together leading world experts in immunology, oncology and infectious diseases. This scientific excellence is widely recognized by the patients’ associations specialized in the field of blood-related diseases that have supported CRYOSTEM since its inception.